AFYA Afya

Afya Limited Announces the Appointment of New Independent Member of Board of Directors and Audit Committee

Afya Limited Announces the Appointment of New Independent Member of Board of Directors and Audit Committee

NOVA LIMA, Brazil, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA) today announced the appointment of Rafael Munerato de Almeida to its board of directors and audit committee as an independent member, effective as of today.

Mr. Munerato was a member of the board of directors of Medcel Editora e Eventos S.A. from February 2016 to March 2019. Mr. Munerato provides medical services for D’Or Consultoria em Corretagem de Seguros e Benefícios Ltda., Funcional Health Tech Soluções em Saúde Ltda., Associação Beneficiente Bom Samaritano, Hospital Bom Samaritano de Maringá S.A., IBES - Instituto Brasileiro para Excelência em Saúde and Trigger Participação e Administração S.A. Mr. Munerato also provides medical services through his private medical practice, is a director at IBES - Instituto Brasileiro para Excelência em Saúde, and a consultant at Multivida Participações S.A., Grupo Kronberg, Switzerland Global Enterprise and CBEXs - Colégio Brasileiro de Executivos da Saúde. He holds a degree in medicine from Santa Casa de Misericórdia de SP, a residency in clinical medicine from Santa Casa de Misericórdia de SP, a residency in cardiology from InCor FMUSP, a specialization in cardiac arrhythmia from InCor FMUSP, and an MBA in health management from FGV.

Mr. Munerato’s appointment increases the size of Afya’s board of directors to nine directors.

About Afya

Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduation program, and continuing medical education activities.

Contact: Investor Relations:

EN
30/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Afya

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommen...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakouts Proliferate; Bullish Outlook Intact The S&P 500, Nasdaq 100, and DJI are breaking out to new all-time highs following 3-week consolidations, while the small-cap Russell 2000 (IWM), mid-cap S&P 400 (IJH), Vanguard Extended Market ETF (VXF), and countless other Sectors/industries are breaking out from 3-week bullish falling wedge/flag patterns. This is classic bull market behavior. Considering market dynamics remain healthy, this is all evidence that supports our ongoing bullish outlook...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Year-End Rally to Continue? The broad equity market has been on an absolute tear since we discussed in our 10/31/23 Compass how risk/reward favored buyers as key supports were being tested, including 4165 on the S&P 500, $162-$163 on the Russell 2000 (IWM), and $350 on the Nasdaq 100 (QQQ). Furthermore, we discussed in our 11/7/23 Compass our belief that this was more than just another counter-trend rally, and that it is likely the start of a significant year-end rally. We also reiterated our b...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Breadth Divergences Persist The S&P 500 is just below 4165-4200 support, and the Nasdaq 100 (QQQ) is just below $350-$355 support. Given they were only 1%-1.5% below these supports at last week's lows, we cannot call them "decisive" breakdowns quite yet. Regardless, these levels are now resistance (in addition to the 200-day MA on SPX), and they are important lines-in-the-sand moving forward. We cannot be bullish if the SPX and QQQ are below the aforementioned levels, but it would be bu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch